We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Malfunctioning microRNAs Linked to Development of Lupus in Mouse Models

By LabMedica International staff writers
Posted on 16 Feb 2011
Another important regulatory role has been identified for microRNA, this time in activating molecular pathways leading to development of the severe autoimmune disorder lupus.

Lupus, which affects more than five million people worldwide, is a chronic autoimmune disease of connective tissue that causes the body's immune system to become hyperactive and attack normal, healthy tissue. More...
The processes leading to development of lupus have so far not been identified.

In an effort to rectify the situation, investigators at Virginia Polytechnic Institute and State University (Blacksburg, USA) used miRNA microarray assays and RT- (real-time)-PCR to measure miRNA expressions in splenic lymphocytes from three mouse lupus models (MRL-lpr, B6-lpr, and NZB/WF1) with different genetic backgrounds. The different models were distinguished by the age at which the animals began to develop lupus (as early as three months or as late as nine months, depending on the strain).

Results published in the December 10, 2010, online edition of the journal PLoS One revealed that despite the genetic differences among the three lupus stains, a common set of dysregulated miRNAs (miR-182-96-183 cluster, miR-31, and miR-155) was present in splenocytes that differed from the miRNAs found in age-matched control mice. The association of these miRNAs with the disease was highlighted by the observation that this miRNA expression pattern became evident in NZB/WF1 mice only at the age when lupus disease was manifested.

Given that miRNAs are conserved, with regard to both evolution and function, the observation of a common lupus disease-associated miRNA expression pattern in mouse lupus models is likely to have significant pathogenic, diagnostic, and/or therapeutic implications for human lupus.

"In the short term, we want to use our better understanding of the disease to develop a tool in the form of molecular markers for early, reliable diagnosis,” said senior author Dr. S. Ansar Ahmed, professor of immunology at Virginia Polytechnic Institute and State University. "The long-term goal is to offer entirely new therapeutic approaches, such as manipulation of lupus-related miRNA, to correct pathological conditions.”

"If we can do this in a mouse model and then to cure other animals, hopefully it can one day be done in humans,” said Dr. Ahmed. "This is long-range research but modern technology is narrowing the time it takes from mouse to human — speeding translation.”

Related Links:
Virginia Polytechnic Institute and State University



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.